Johnson & Johnson (JNJ)

$263.04 +9.06 (3.57%)
Market Cap 633.19B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.67
Forward PE 22.74
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 8,000,700
Avg Vol 8,198,988
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 100%
Beta 0.24
Analysts Strong Sell
Price Target $260.04

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
GordoHLYK13
GordoHLYK13 Jul. 5 at 1:15 PM
$IGC $JNJ $LLY $PFE $IGC is still valued around a ~$30M market cap. If Phase 2 CALMA delivers strong topline results, management believes the company could be re-rated closer to peers at a $300M–$500M valuation. That’s a potential 10x–16.6x increase in market value. Using a ~$0.27 share price as a baseline, that equates to roughly $2.70–$4.50 per share. Phase 2 data is the key catalyst that could determine whether the market assigns that higher valuation.
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 5 at 1:00 PM
$IGC $IGC is flying under the radar. 🧠 Phase 2 IGC-AD1/CALMA is nearing completion with topline data expected in the coming months. A patented, easy-to-administer liquid therapy has shown rapid Phase 2 efficacy in as little as 2 weeks for Alzheimer’s agitation. With a market cap around $30M, low cash burn, a massive unmet market, and peer biotechs historically re-rating 10x+ on positive Phase 2 data, the risk/reward is hard to ignore. Eyes on the catalyst. 🚀 $LLY $BIIB $JNJ $PFE #Alzheimers #Biotech https://youtu.be/87NG8ioxSw4?is=AY9ZnJw5__5pn_fM
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 5 at 9:19 AM
📢 $JNJ Bullish Rally Targets $271.37+ 💊 Johnson & Johnson is unfolding a strong Elliott Wave bullish sequence. The structure favors continued upside, with momentum pointing toward $271.37 and beyond as the cycle extends higher. 📈 Read the Full analysis of JNJ bullish cycle 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #ElliottWave #Trading #Stocks
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
TomMac64
TomMac64 Jul. 4 at 10:29 AM
$JNJ $LLY $MRNA $VNDA Doesn’t have to be at $30 + what’s wrong with $15 + the OS float is 60M that’s after 20 years public …. AMAZING !
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC Bullish: CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s serious skin in the game. Their restricted Rule 144 shares mean no immediate insider dumping pressure. Balance sheet is stronger, cash is preserved, and insiders look locked & loaded ahead of the Phase 2 CALMA trial results. If the data is positive, expect a lot more eyes on igc 👀🚀 Tags: $LLY $JNJ $PFE $MRK
1 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s real skin in the game. Those are restricted Rule 144 shares, so there’s no immediate insider dumping pressure. They cleaned up the balance sheet, preserved cash, and look locked & loaded ahead of the upcoming Phase 2 CALMA trial results. Insiders don’t increase their equity exposure by millions of shares unless they see potential upside—but clinical trial outcomes remain uncertain until the data is released. 🚀📈 https://www.getnews.info/story/2026/07/01/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-42-million-shares/ $LLY $JNJ $PFE $MRK
0 · Reply
Investor203
Investor203 Jul. 4 at 5:39 AM
$MRNA who is buying $VNDA at $30+? $JNJ $LLY or someone else
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 3 at 8:45 PM
How confident are you at identifying a bullish continuation before it accelerates? $JNJ’s structure points to more upside — wave (3) pushing toward 261–269, then a break above 271.37 unlocks higher targets. Master this methodology 👉 elliottwave-forecast.com #Stocks #JNJ #MarketAnalysis
0 · Reply
PivotPoint_101
PivotPoint_101 Jul. 3 at 5:15 PM
$SPY $QQQ $JNJ #pivotgroup🎬🎁 $MRNA 🔐🏦 Sold the 9/18 Held the 1/15 for dip add+ $100 Later
0 · Reply
Latest News on JNJ
Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 8 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

2026-06-26T16:40:11.000Z - 8 days ago

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 8 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

2026-06-26T12:36:03.000Z - 9 days ago

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

2026-06-25T09:10:22.000Z - 10 days ago

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 10 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

2026-06-16T20:26:11.000Z - 18 days ago

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

AMCR LOW

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

2026-06-15T11:17:46.000Z - 20 days ago

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

Johnson & Johnson invests more than $1B in Jacksonville, Florida

2026-06-15T10:05:07.000Z - 20 days ago

Johnson & Johnson invests more than $1B in Jacksonville, Florida

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 20 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 22 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 22 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

2026-06-11T11:50:10.000Z - 24 days ago

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 24 days ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 24 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

Johnson & Johnson presents first results from ENERGY study

2026-06-11T09:26:54.000Z - 24 days ago

Johnson & Johnson presents first results from ENERGY study

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 24 days ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 25 days ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 25 days ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 26 days ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 26 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 27 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

2026-06-08T13:00:56.000Z - 27 days ago

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 27 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 8, 2026, 8:00 AM EDT - 27 days ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 5, 2026, 6:24 PM EDT - 4 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Jun 3, 2026, 12:04 AM EDT - 4 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 3, 2026, 12:03 AM EDT - 4 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

Jun 2, 2026, 6:24 PM EDT - 4 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:39 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:29 AM EDT - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:27 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 31, 2026, 8:01 AM EDT - 5 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 2:00 PM EDT - 5 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 29, 2026, 8:18 AM EDT - 5 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 7:10 PM EDT - 5 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 28, 2026, 5:30 AM EDT - 5 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 4:22 PM EDT - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 27, 2026, 11:00 AM EDT - 5 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 7:00 AM EDT - 6 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 6 weeks ago

Johnson & Johnson says nipocalimab approved in China

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:30 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 19, 2026, 9:00 AM EDT - 6 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14, 2026, 4:01 PM EDT - 7 weeks ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:20 PM EDT - 7 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 12, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 4:34 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 11, 2026, 8:00 AM EDT - 7 weeks ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 11:34 AM EDT - 2 months ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

MO

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 7, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 5, 2026, 7:00 AM EDT - 2 months ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 4, 2026, 8:00 AM EDT - 2 months ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 30, 2026, 8:02 AM EDT - 2 months ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 4:33 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 27, 2026, 8:03 AM EDT - 2 months ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 24, 2026, 4:30 PM EDT - 2 months ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Cramer says look to these 4 stocks to go with your high-flying tech names

Apr 23, 2026, 6:44 PM EDT - 2 months ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

GordoHLYK13
GordoHLYK13 Jul. 5 at 1:15 PM
$IGC $JNJ $LLY $PFE $IGC is still valued around a ~$30M market cap. If Phase 2 CALMA delivers strong topline results, management believes the company could be re-rated closer to peers at a $300M–$500M valuation. That’s a potential 10x–16.6x increase in market value. Using a ~$0.27 share price as a baseline, that equates to roughly $2.70–$4.50 per share. Phase 2 data is the key catalyst that could determine whether the market assigns that higher valuation.
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 5 at 1:00 PM
$IGC $IGC is flying under the radar. 🧠 Phase 2 IGC-AD1/CALMA is nearing completion with topline data expected in the coming months. A patented, easy-to-administer liquid therapy has shown rapid Phase 2 efficacy in as little as 2 weeks for Alzheimer’s agitation. With a market cap around $30M, low cash burn, a massive unmet market, and peer biotechs historically re-rating 10x+ on positive Phase 2 data, the risk/reward is hard to ignore. Eyes on the catalyst. 🚀 $LLY $BIIB $JNJ $PFE #Alzheimers #Biotech https://youtu.be/87NG8ioxSw4?is=AY9ZnJw5__5pn_fM
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 5 at 9:19 AM
📢 $JNJ Bullish Rally Targets $271.37+ 💊 Johnson & Johnson is unfolding a strong Elliott Wave bullish sequence. The structure favors continued upside, with momentum pointing toward $271.37 and beyond as the cycle extends higher. 📈 Read the Full analysis of JNJ bullish cycle 👉 https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #ElliottWave #Trading #Stocks
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
TomMac64
TomMac64 Jul. 4 at 10:29 AM
$JNJ $LLY $MRNA $VNDA Doesn’t have to be at $30 + what’s wrong with $15 + the OS float is 60M that’s after 20 years public …. AMAZING !
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC Bullish: CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s serious skin in the game. Their restricted Rule 144 shares mean no immediate insider dumping pressure. Balance sheet is stronger, cash is preserved, and insiders look locked & loaded ahead of the Phase 2 CALMA trial results. If the data is positive, expect a lot more eyes on igc 👀🚀 Tags: $LLY $JNJ $PFE $MRK
1 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s real skin in the game. Those are restricted Rule 144 shares, so there’s no immediate insider dumping pressure. They cleaned up the balance sheet, preserved cash, and look locked & loaded ahead of the upcoming Phase 2 CALMA trial results. Insiders don’t increase their equity exposure by millions of shares unless they see potential upside—but clinical trial outcomes remain uncertain until the data is released. 🚀📈 https://www.getnews.info/story/2026/07/01/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-42-million-shares/ $LLY $JNJ $PFE $MRK
0 · Reply
Investor203
Investor203 Jul. 4 at 5:39 AM
$MRNA who is buying $VNDA at $30+? $JNJ $LLY or someone else
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 3 at 8:45 PM
How confident are you at identifying a bullish continuation before it accelerates? $JNJ’s structure points to more upside — wave (3) pushing toward 261–269, then a break above 271.37 unlocks higher targets. Master this methodology 👉 elliottwave-forecast.com #Stocks #JNJ #MarketAnalysis
0 · Reply
PivotPoint_101
PivotPoint_101 Jul. 3 at 5:15 PM
$SPY $QQQ $JNJ #pivotgroup🎬🎁 $MRNA 🔐🏦 Sold the 9/18 Held the 1/15 for dip add+ $100 Later
0 · Reply
Breton2018
Breton2018 Jul. 3 at 11:11 AM
$JNJ Price increase from analysts
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 3 at 10:55 AM
$JNJ favors rally in bull run targeting 271.4 - 305.2 area against June-2026 low Buyers remain in control in short term pullback to extend rally within January-2025 low in daily. https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
cwEWF
cwEWF Jul. 3 at 10:11 AM
$JNJ extending higher targeting 271.3 - 305.2 area from daily #Bluebox area Check out the article for more details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
justiceforb_85
justiceforb_85 Jul. 2 at 11:08 PM
$NBTX started a position. Data presented thus far for NBTXR3 appears promising and could see this as a BO candidate for $JNJ.
0 · Reply
Godsgrace2025
Godsgrace2025 Jul. 2 at 8:31 PM
$QQQ $MLTX $JNJ $GME Hope Everyone a has A Great 4th of July God is Good
0 · Reply
PrnceMichael
PrnceMichael Jul. 2 at 4:51 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
TraderDaKing
TraderDaKing Jul. 2 at 4:21 PM
$GME $DJT $WEN $JNJ $BAC $BAC
0 · Reply
TraderDaKing
TraderDaKing Jul. 2 at 4:17 PM
$GME $AMC $PFE $JNJ Roaring Kitty may be a new board member. Welcome to New Jersey. ELTP is the new MEME stock of 2026 and 2027 Many people are talking about SequestOx.........
0 · Reply
howardlindzon
howardlindzon Jul. 2 at 2:49 PM
best looking charts in healthcare $ABBV $ARWR $GLSI $JNJ $LLY
0 · Reply
Estimize
Estimize Jul. 2 at 2:12 PM
Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 2 at 1:33 PM
$JNJ $PFE $MSOS $BYND
0 · Reply